Drug · DIN 02212366
ZANTAC
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since August 31, 2018; first marketed May 1, 2000.
- Drug Identification Number (DIN)
- 02212366
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Intravenous; Intramuscular
- Therapeutic class (ATC)
- Ranitidine A02BA02
- Class
- Human
- Record last updated
- June 25, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RANITIDINE (RANITIDINE HYDROCHLORIDE) | 50 MG | 2 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- July 19, 2001: NOC 2547New Drug Submission (NDS) · Change in manufacturer name
- March 7, 1996: NOC 4630New Drug Submission (NDS)
Other DINs named ZANTAC
- DIN 00603791 · Cancelled Post Market
- DIN 02212331 · Cancelled Post Market
- DIN 02212358 · Cancelled Post Market
- DIN 02212374 · Cancelled Post Market
- DIN 02230287 · Cancelled Post Market